Navigation Links
Medarex to Present at the 27th Annual J.P. Morgan Healthcare Conference
Date:1/6/2009

PRINCETON, N.J., Jan. 6 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today that it is scheduled to present at the 27th Annual J.P. Morgan Healthcare Conference at 8:30 a.m. Pacific Time (11:30 a.m. Eastern Time) on Tuesday, January 13, 2009. The event will be webcast live and will be available in the Investor Relations section of the Medarex website at www.medarex.com. An archived edition of the presentation will be available following the event.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. Over forty of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with the most advanced product candidates currently in Phase 3 clinical trials, the subject of regulatory applications for marketing authorization or approved in Canada. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at www.medarex.com.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.

    Contact: Laura S. Choi                   Nichol Ochsner

'/>"/>
SOURCE Medarex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Medarex to Present at the RBC Capital Markets Healthcare Conference
2. Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD)
3. Medarex Announces 2008 Third Quarter Financial Results
4. Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Valortim(R)
5. Medarex to Present at the UBS Global Life Sciences Conference
6. Medarex to Present at the Thomas Weisel Partners Healthcare Conference
7. BioWa and Medarex Announce License of BioWas COMPLEGENT(TM) Technology
8. Medarex Announces July 10 Live Webcast of R&D Day Event
9. Medarex to Present at the Jefferies Second Annual Healthcare Conference
10. Medarex to Present at the 29th Annual Goldman Sachs Healthcare Conference
11. Medarex to Present at the Bank of America 2008 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 Cynvenio, a cancer diagnostics ... the genomic analysis of tumor cells in the bloodstream, ... web-based cancer decision support application powered by CollabRx, Inc. ... ClearID™ genomic test, Therapy Finder will provide breast cancer ...
(Date:1/15/2014)... 15, 2014 More than 5 million ... 1 in 3 seniors will die with Alzheimer’s or ... jaw-dropping figures have shocked many Americans into looking for ... prevent these tragic age-related cognitive disorders. Jonathan Weisman, president ...
(Date:1/15/2014)... Sunnyvale, CA (PRWEB) January 15, 2014 ... throughput research solutions, today announced that Lupin Limited, one ... of Freeslate’s CM Protégé PharmD System for ... in Mumbai, India, is focused on a wide range ...
(Date:1/14/2014)... CA (PRWEB) January 14, 2014 Histogen, ... the products of cells grown under simulated embryonic conditions, ... license agreement with Suneva Medical, Inc. for physician-dispensed aesthetic ... , This agreement is an amendment to ...
Breaking Biology Technology:Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3
... Modeling Complex ... Biological Systems for Type 2 Diabetes, CAMBRIDGE, Mass., ... on identifying molecular mechanisms, networks and,biomarkers to better understand ... Sirtris Pharmaceuticals, Inc. (Nasdaq: SIRT ),a biopharmaceutical company ...
... CHURCH, Va., April 30 Computer Sciences,Corporation (NYSE: ... M. Wah, chief,medical officer and vice president of ... ranked number 10 in Modern Physician and Modern,Healthcare ... Physician,Executives, published in April. Readers from both magazines ...
... XI,AN, China, April 30 /Xinhua-PRNewswire-FirstCall/ -- Huifeng,Bio-Pharmaceutical ... leading,developer and producer of plant extracts and ... and food production, today,announced that it will ... March 31 on Thursday, May 15, 2008, ...
Cached Biology Technology:Genstruct and Sirtris Pharmaceuticals Win Bio-IT World's Best Practices Award 2CSC's Dr. Robert M. Wah Makes Top 10 in 50 Most Powerful Physician Executives List 2
(Date:4/17/2014)... peppers. Information about archaeological remains of ancient chili peppers ... of words for chili peppers in ancient dialects helped ... the value of multi-proxy data analysis. Their results are ... presented in a special feature issue of the ... plant and animal domestication edited by Dolores Piperno, staff ...
(Date:4/17/2014)... April 16, 2014. Kessler Foundation has been named ... from the Department of Defense Spinal Cord Injury ... investigator for the randomized, double-blinded, controlled, multi-site clinical ... and muscle strength after spinal cord injury. Dr. ... Engineering Research at Kessler Foundation. Two additional sites ...
(Date:4/17/2014)... Professor Marc Andr Gauthier and Professor Luca Razzari ... each been awarded large grants from the John ... for Innovation (CFI) for the acquisition of state-of-the-art ... be added matching grants from the Ministre de ... et de la Technologie (MESRST). These new laboratories ...
Breaking Biology News(10 mins):Chickens to chili peppers 2Chickens to chili peppers 3Kessler Foundation awarded Department of Defense grant for spinal cord injury research 2New state-of-the-art biotech and nanotech equipment for INRS 2
... have extraordinarily small balance organs, and scientists have long ... School of Medicine in St. Louis has contradicted a ... heads so vigorously that they had to have smaller, ... Working with a Midwestern zoo and a local ...
... be promising candidates for drug development has become easier ... medicinal chemistry group. Dr Jonathan Baell and Dr ... can be used to weed out those molecules likely ... chemical library for compounds that could be useful in ...
... ─ The National Institutes of Health has awarded Albert ... to combat childhood obesity in the Bronx. Working with ... Center for Einstein, a team of researchers will build ... the classroom to encourage physical activity and promote positive ...
Cached Biology News:Rodeo bull goes head-to-head with zoo dolphins in a study of balance 2Rodeo bull goes head-to-head with zoo dolphins in a study of balance 3Compound screening for drug development made simpler 2Einstein-Montefiore research tackles childhood obesity in the Bronx 2Einstein-Montefiore research tackles childhood obesity in the Bronx 3